Table 4.
Demographic and clinical characteristics of the marker-positive subgroup of cohort II
| No marker combination (n = 37) | Marker combination (n = 13) | F(df1, df2) | P | |||
|---|---|---|---|---|---|---|
| M | (SD) | M | (SD) | |||
| Age | 32.24 | (11.13) | 40 | (11.19) | 4.66 (1, 48) | 0.036* |
| Duration of illness | 8.55 | (9.04) | 9.54 | (8.33) | 0.12 (1, 48) | 0.732 |
| Hospitalizations | 4.03 | (3.33) | 3.15 | (1.57) | 1.54 (1, 43.31) | 0.222 |
| PANSS total | 61.67 | (17.50) | 54.92 | (12.44) | 1.62 (1, 47) | 0.209 |
| PANSS positive | 14.03 | (5.59) | 11.54 | (3.57) | 2.23 (1, 47) | 0.142 |
| PANSS negative | 16.75 | (5.12) | 16.69 | (6.58) | <0.01 (1, 47) | 0.125 |
| PANSS general | 30.89 | (9.31) | 26.69 | (4.11) | 4.75 (1, 44.86) | 0.035* |
| No marker combination (n = 37) | Marker combination (n = 13) | |||
|---|---|---|---|---|
| Mdn | Mdn | U | P | |
| CPZ | 467.86 | 467.5 | 253.5 | 0.773 |
| Age of onset | 21 | 30 | 331 | 0.045* |
| Educational years | 13 | 16 | 321.5 | 0.072 |
| No marker combination (n = 37) | Marker combination (n = 13) | χ2(df1) | P | |
|---|---|---|---|---|
| Sex (male:female) | 29:9 | 8:2 | 0.45 (1) | 0.503 |
| Clozapine users (yes:no) | 5:32 | 8:5 | 3.74 (1) | 0.053 |
| Language (German:foreign) | 30:7 | 13:0 | 2.86 (1) | 0.091 |
| Handedness (right:left:both) | 33:4:0 | 11:1:1 | 2.96 (2) | 0.227 |
CPZ chlorpromazine equivalents (cross-sectional at day of blood drawing), PANSS positive and negative syndrome scale, M mean, SD standard deviation, Mdn median, df degree of freedom, F F statistic, U Mann–Whitney-U, P p-value
Statistics represent the comparison of the patient groups with and without the marker combination